The CITADEL-204 and 205 study is testing an investigational drug. This means the drug is not approved by the US Food and Drug Administration (FDA) for use in relapsed or refractory marginal zone lymphoma (MZL).
During the study, you may undergo the following:
You will need to get a complete physical exam to see if you are eligible for the study. During that screening, you will need to
Give blood samples
Have an electrocardiogram (ECG), a test that checks the condition of your heart
Have a computed tomography (CT) or magnetic resonance imaging (MRI) scan
Have a tumor biopsy and a bone marrow biopsy if you have not had them recently
The study drug will be provided at no cost to you. The study team may help you check with your health plan and your doctor about any costs related to the study. Your routine medical care will be billed to you or your insurer in the ordinary manner. You will not be paid for being in the study.
Interested to enroll in a study?
See if you qualify today